MS Views and News Be empowered with MS views and news. CLICK HERE - - to SUBSCRIBE for The MS BEACON e-Newsletter

MS Views and News uses state-of-the-art technology to provide resources to the MS Community. Visit our MS learning channel on YouTube, to gain knowledge from hundreds of MS educational videos presented by MS Experts from across the USA. Click:

Within this blog you can find MS resources by viewing all showing below pertaining to thousands of MS articles, resources, event timing. Additionally, please visit our Social media platforms: Facebook, Twitter, and Instagram . Each providing important information for those affected by Multiple Sclerosis. * From the comfort of your home, you can join us for our VIRTUAL MS events. To learn more of these virtual events please subscribe here.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, for your personal knowledge and to keep you informed of current health-related issues. It is not a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.


Saturday, October 1, 2016

CME report - Exercise Won't Keep MS at Bay for Women


Click here to receive MS news via e-mail

Analysis of Nurses Health Study cohorts suggests no protective effect

Contributing Writer, MedPage Today

MS Views and News
Providing educational information, resources and services for those affected by MS

Friday, September 30, 2016

Future MS Treatment: Selectively Targeting T-cells May Come As Temporary Tattoo


Antioxidant-filled nano-particles injected under the skin may become a future multiple sclerosis (MS) treatment that comes with a perk or a drawback, depending on how a patient sees it.  The injection leaves a temporary dark spot on the skin, resembling a tattoo.
The tattoo might be a small issue considering that the particles have a huge advantage. They only inactivate immune T-cells — the main cell type driving MS — leaving other immune cells unaffected, potentially reducing side effects.
The proof-of-concept study, “Preferential uptake of antioxidant carbon nanoparticles by T lymphocytes for immunomodulation,” published in the journal Scientific Reports, was a joint effort between researchers at Baylor College of Medicine and Rice University, both in Texas.
Continue Reading

MS Views and News
Providing educational information, resources and services for those affected by MS

Thursday, September 29, 2016

Research organization searching for MS patients for future studies


Click here to receive MS news via e-mail

The Henne Group is a research organization based in San Francisco. We are looking for individuals interested in joining our panel and participate in future research projects about their experience living with Multiple Sclerosis (MS).

If you are interested or know of someone who would be, you can follow this link to sign up:

If you have any questions you may call 415 - 348 - 2936

MS Views and News
Providing educational information, resources and services for those affected by MS

Biogen is proud to announce the launch of a new phase of Reimagine MySelf™


Click here to receive MS news via e-mail

Biogen is proud to announce the launch of a new phase of Reimagine MySelf™, a program encouraging people living with relapsing multiple sclerosis (MS) to reimagine life with the chronic disease. 

First introduced in 2015, Reimagine MySelf now includes a new online resource that provides visitors with access to personal stories and ideas from people living with relapsing MS that are being treated with Tecfidera® (dimethyl fumarate), those with personal connections to the disease and insights from MS experts.
Reimagine MySelf encourages those living with relapsing MS to make small, impactful changes that could make a difference in life with the disease. This year, visitors can hear from actress Jamie-Lynn Sigler, who announced earlier this year that she is living with relapsing MS. She is sharing more details of her experience with the disease, including how she is navigating parenting, marriage and career, the importance of her support system, her treatment plan and more.
“One of the biggest lessons I’ve learned–and that I hope to share with others–is that this disease is a part of me, but it doesn’t define who I am,” said Jamie. “I’ve received such overwhelming support and love from everyone–especially the MS community–that my goal is to now help others living with MS reimagine aspects of their own lives, the same way that I have been able to do.”
In addition to Jamie, Jeannie Mai, style expert and co-host of the daytime talk show “The Real,” and Chef Ben Ford–both of whom have family connections to MS–are also providing accessible ideas on the site, specifically curated for those living with the disease.

These program ambassadors, along with physicians and MS peer speakers, will have the chance to meet with people in the MS community and talk more about both relapsing MS and treatment options like TECFIDERA at local events in Los Angeles and Houston later this year. As part of these events, different program ambassadors will conduct in-person demonstrations showing how to reimagine aspects of life–like personal style and cooking–related to their personal areas of expertise. Those interested in attending can register at

We would really appreciate if you would consider sharing details about the Reimagine MySelf program with your constituents. This resource is now available for the MS community at, and will be updated regularly with new stories and information about registering for local events.

Please feel free to reach out with any questions or requests for additional information. 

Important Safety Information and Indication

Do not use TECFIDERA if you have had an allergic reaction (such as welts, hives, swelling of the face, lips, mouth or tongue, or difficulty breathing) to TECFIDERA or any of its ingredients.

Before taking and while you take TECFIDERA, tell your doctor about any low white blood cell counts or infections or any other medical conditions.

What are the possible side effects of TECFIDERA?

TECFIDERA may cause serious side effects including allergic reactions, PML, which is a rare brain infection that usually leads to death or severe disability, and decreases in your white blood cell count. Your doctor may check your white blood cell count before you take TECFIDERA and from time to time during treatment.

The most common side effects of TECFIDERA include flushing and stomach problems. These can happen especially at the start of treatment and may decrease over time. Taking TECFIDERA with food may help reduce flushing. Call your doctor if these symptoms bother you or do not go away. Ask your doctor if taking aspirin before taking TECFIDERA may reduce flushing.

These are not all the possible side effects of TECFIDERA. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. For more information go to

Tell your doctor if you are pregnant or plan to become pregnant, or breastfeeding or plan to breastfeed. It is not known if TECFIDERA will harm your unborn baby or if it passes into your breast milk. Also tell your doctor if you are taking prescription or over-the-counter medicines, vitamins, or herbal supplements.

For additional important safety information, please see full Prescribing Information and Patient Information. This is not intended to replace discussions with your doctor.


Tecfidera® (dimethyl fumarate) is a prescription medicine used to treat people with relapsing forms of multiple sclerosis.

MS Views and News
Providing educational information, resources and services for those affected by MS

Wednesday, September 28, 2016

StemGenex CSO Tells FDA at Hearing to Regulate Adult Stem Cell Therapies as 'Blood Tissue


Click here to receive MS news via e-mail

In a presentation at a U.S. Food and Drug Administration (FDA) public hearing earlier this month, the chief scientific officer of StemGenex Medical Group, Steven A. Brody, MD, PhD, said succinctly: “Stem cells have arrived and have captivated the scientific and medical communities. With this excitement comes responsibility and with this responsibility comes regulation.”
Steven Brody
Dr. Steven Brody (Courtesy of StemGenex)

The purpose of the FDA hearings, held at National Institutes of Health (NIH) facilities in Bethesda, Maryland, on Sept. 12–13, was to obtain comments on four Draft Guidances of Human Cells, Tissues and Cellular and Tissue-Based Products relating to the regulation of adult stem cell therapies from a broad range of stakeholders, including  healthcare professionals, clinicians, biomedical researchers, patients, tissue establishments, biological and device product manufacturers, and the public.
The FDA asked for feedback on the scope of its draft guidelines, ranging from the particular topics covered and questions posed, to the identification of additional issues not covered but for which guidance would be helpful, and whether the FDA’s recommendations for each topic were sufficiently clear and consistent to provide meaningful guidance.

MS Views and News
Providing educational information, resources and services for those affected by MS

Change in Clinical Test Dose of Potential MS Therapy, Laquinimod, Triggers FDA Response


Click here to receive MS news via e-mail

Active Biotech acknowledged in an update on laquinimod, the oral small molecule being developed by Teva Pharmaceutical Industries to treat multiple sclerosis (MS) and Huntington’s disease (HD), that the U.S. Food and Drug Administration (FDA) has rescinded the special protocol assessment given to a Phase 3 study of the treatment in relapsing MS patients because of a dose change that — necessarily, the company said — was made without prior FDA approval.
Laquinimod, which Active and Teva are working together to develop, is being evaluated for safety, efficacy and tolerability in the CONCERTO study (NCT01707992), a double-blind and placebo-controlled trial that was investigating two oral doses of laquinimod — 0.6 mg/day or 1.2mg/day — in relapsing MS patients. But the Data Monitoring Committee (DMC) supervising this trial and a similar study in progressive MS patients recommended use of higher doses be discontinued immediately in January, after cardiovascular events were reported in eight patients (none fatal) — seven in the relapsing MS and one in the progressive MS studies.

MS Views and News
Providing educational information, resources and services for those affected by MS

Patient preferences for treatment of multiple sclerosis with disease-modifying therapies: a discrete choice experiment


Click here to receive MS news via e-mail

Objectives: To assess disease-modifying therapy (DMT) preferences in a population of patients with multiple sclerosis (MS) and to estimate the association between sociodemographic and clinical factors and these preferences.
Methods: Preferences for DMTs attributes were measured using a discrete choice experiment. Analysis of preferences was assessed using mixed-logit hierarchical Bayes regression. A multilinear regression was used to evaluate the association between the preferences for each attribute and patients’ demographic and clinical characteristics. A Student’s t-test or Welch’s t-test was used for subgroup comparisons.
Results: A total of 125 patients were included in the final analysis (62.9% female, mean age 44.5 years, 71.5% with relapsing-remitting MS diagnosis). The most important factor for patients was the possibility of suffering from the side effects of the treatment (relative importance [RI] =50%), followed by a delay in disease progression (RI =19.4%), and route and frequency of administration (RI =14.3%). According to maximum acceptable risk, patients were willing to accept an increase of 3.8% in severity of side effects, for a delay of 1 year in disease progression. Treatment duration was the most prevalent factor affecting preferences, followed by the age of patients, type of MS, level of education, and the type of current treatment. Patients treated orally were significantly more concerned about the route and frequency of administration (P=0.026) than patients on injectable therapy. Naïve patients stated significantly less importance to prevention of relapses (P=0.021) and deterioration of the capacity for performing usual daily life activities (P=0.015). Finally, patients with >5 years since diagnosis were significantly less concerned about preventing disease progression (P=0.021), and more concerned about treatment side effects (P=0.052) than compared with patients with <5 years of MS history.
 The most important attribute for MS patients was side effects of DMTs, followed by delay in disability progression. Experience with DMTs and time since MS diagnosis changed patients’ preferences. These results give information to adjust new DMT treatment in order to satisfy patients’ preferences and therefore, improve adherence to treatment.

READ COMPLETE Article found here

MS Views and News
Providing educational information, resources and services for those affected by MS

Geneuro Tries A Different Take On Multiple Sclerosis


Click here to receive MS news via e-mail

September 26, 2016

Multiple sclerosis therapies have so far largely focused on reducing inflammation or suppressing the immune response that leads to episodes of nervous system damage. Switzerland-based Geneuro is seeking to block a protein that triggers these downstream biological activities.
An investment from Servier and cash from an initial public offering earlier this year are backing a hypothesis that inhibiting multiple sclerosis-associated retrovirus envelope protein (MSRVenv) could slow the progress of the disease without raising the risk of infection. “Most of the drugs that exist today – which are great drugs and have reduced the number of flares – have been able to lower the number of attacks because they’ve been able to diminish the immune response,” says Geneuro’s chief executive, Jesus Martin-Garcia. “We don’t touch the immune system.”
Invasive genes
The agent, called GNbAC1, is a MAb blocking MSRVenv. In December, Geneuro launched a phase IIb European trial enrolling 260 patients with the hope of showing that neutralising MSRVenv can modify the growth of brain lesions that lead to disability in patients with the relapsing-remitting form of the disease – secondary endpoints will look for clinical improvement and signs of remyelination.
Earlier this month the trial, Change-MS, reached its halfway enrollment point. A focus on MSRVenv grew out of research on human endogenous retroviruses, or viral DNA that has been inserted into human genetic material – representing about 8% of human genes. MSRV is one of these, and is silent in most people – but in MS patients it appears to be active because MSRVenv has been found in their bloodstreams and brain lesions.

MS Views and News
Providing educational information, resources and services for those affected by MS

Furor over drug prices puts Patient Advocacy Groups in a Bind


Click here to receive MS news via e-mail

September 28, 2016

Link to NYTimes story:  click here 

MS Views and News
Providing educational information, resources and services for those affected by MS

Tuesday, September 27, 2016

Pain and MS


Click here to receive MS news via e-mail

One of the common myths and misconceptions about MS is that it is a painless condition. Unfortunately in the past many people's pain was dismissed. As a MS clinician and patient I can tell you with absolute certainty that MS pain is real, and there are ways to manage it! Talk to your neurologist if you have nerve pain, trigeminal neuralgia, muscle spasticity, the MS "hug", headaches, or any other symptom that is interfering with you daily life. For more information you can head to the MS society's website, or

MS Views and News
Providing educational information, resources and services for those affected by MS

Multiple Sclerosis and Depression


Click here to receive MS news via e-mail

Many people with MS also havedepression. In fact, about half of all people with multiple sclerosiswill need treatment for the condition at some point.
If you have MS and you've also felt sad for a while, you don’t have to handle it alone. Talk to your doctor about how you’re feeling, and see if there are any treatments that can help you.

What’s the Link?

Anyone dealing with too much stress or a tough situation might havedepression. It’s easy to understand how MS, which takes a toll on physical health and may cause lasting problems, can bring on the mood disorder.
MS might also cause depression. The disease may destroy the protective coating around nerves that helps the brain send signals that affect mood.
Depression is also a side effect of some the drugs that treat multiple sclerosis, such as steroids or interferon.

What Are the Symptoms of Depression?

MS Views and News
Providing educational information, resources and services for those affected by MS

Plasma Exchange (Plasmapheresis) for MS


Click here to receive MS news via e-mail

Plasma exchange, also known as plasmapheresis, is a way to "clean" your blood. It works sort of like kidney dialysis. During the treatment, plasma -- the liquid part of your blood -- gets replaced with plasma from a donor or with a plasma substitute.
People with some forms of multiple sclerosis use plasma exchange to manage sudden, severe attacks, sometimes called relapses or flare-ups. Their plasma could have certain proteins that are attacking their own body. When you take out the plasma, you get rid of those proteins, and symptoms may get better.

How It Works

You can get plasma exchange in the hospital or at an outpatient center. The process isn't painful, and you won't need anesthesia.
You'll lie in bed or sit in a reclining chair.
A nurse or a specialist will put a needle attached to a thin tube, called a catheter, into a vein in each arm. If your arm veins are too small, you may have to have a needle in your shoulder or groin instead.
Your blood comes out through one of the tubes and goes into a machine that separates your plasma from your blood cells. Then your blood cells get mixed with fresh plasma, and the new blood mixture goes back into your body through the other tube.
Most treatments last 2 to 4 hours, depending on how big your body is and how much plasma gets swapped out. You may need two or three treatments each week for 2 or more weeks.

Side Effects and Risks

MS Views and News
Providing educational information, resources and services for those affected by MS

How Well Are You Managing MS?


Click here to receive MS news via e-mail

This assessment is found at WebMD
  Click here to view 

MS Views and News
Providing educational information, resources and services for those affected by MS